In an era of infinite challenges and finite resources, health systems must employ a rigorous approach to strategic and facility planning.
The Latest
Saint Joseph Mount Sterling (Ky.), part of Lexington, Ky.-based CHI Saint Joseph Health, has partnered with Cleveland Clinic Cancer Center to provide access to specialized care for the region's cancer patients.
As many as 10 percent of insured cancer survivors delayed follow-up care in the previous 12 months due to costs such as deductibles or copays, according to a recent study published in Cancer Medicine.
Rhode Island has the highest percentage of cancer screenings among U.S. adults between the ages of 65 and 75, while Wyoming falls furthest from the national average of 74.1 percent, according to the United Health Foundation.
Los Angeles-based USC Norris Comprehensive Cancer Center is creating cancer wellness hubs throughout the city with the goal of reducing health disparities and improving outcomes.
A community outreach engagement program at Penn Medicine's Abramson Cancer Center in Philadelphia increased the percentage of Black patients in clinical trials from 12 to 24 percent, the health system said May 19.
Breast cancer patients receiving chemotherapy had about the same risk of contracting COVID-19 as those taking cancer drugs that don't weaken the immune system, according to a study led by NYU Langone Health researchers set to be presented June 4…
HPV vaccination rates among adolescents already lagged behind those of other recommended vaccines, with the COVID-19 pandemic further exacerbating it. Now, 72 U.S. cancer centers are urging parents and physicians to prioritize getting children back on track with the vaccine this…
Cervical cancer rates have dropped 1 percent annually since 2001, likely due to clear screening and HPV vaccination guidelines, while other HPV-related cancers without standardized screening guidelines are on the rise, according to research set to be presented at the…
Maria Fardis has submitted her resignation as president, CEO and director of the immune-oncology company Iovance Biotherapeutics, reports the San Francisco Business Times.